Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Jacques

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
European Psychiatry : the Journal of the Association of European Psychiatrists|September 25, 2024
Prevalence of schizophrenia spectrum and other psychotic disorders in problem gambling: A systematic review and meta-analysisOlivier Corbeil, Laurent Béchard, Élizabeth Anderson, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III TrialKatja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
BMC Psychiatry|April 25, 2023
Problem gambling among people with first-episode psychosis: protocol for a prospective multicenter cohort studyOlivier Corbeil, Manuel Soulard, Maxime Huot-Lavoie, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 26, 2016
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in TaiwanShang-Yi Huang, Yuan-Bin Yu, Su-Peng Yeh, et al.
Blood|December 18, 2012
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson, David Siegel, Rachid Baz, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
European Psychiatry : the Journal of the Association of European Psychiatrists|September 25, 2024
Prevalence of schizophrenia spectrum and other psychotic disorders in problem gambling: A systematic review and meta-analysisOlivier Corbeil, Laurent Béchard, Élizabeth Anderson, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III TrialKatja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
BMC Psychiatry|April 25, 2023
Problem gambling among people with first-episode psychosis: protocol for a prospective multicenter cohort studyOlivier Corbeil, Manuel Soulard, Maxime Huot-Lavoie, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 26, 2016
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in TaiwanShang-Yi Huang, Yuan-Bin Yu, Su-Peng Yeh, et al.
Blood|December 18, 2012
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson, David Siegel, Rachid Baz, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Pageof 6